An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations

@inproceedings{Kornek2015AnUO,
  title={An update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerations},
  author={Barbara Kornek},
  booktitle={Patient preference and adherence},
  year={2015}
}
In the context of an increasing repertoire of multiple sclerosis (MS) therapeutics, choosing the appropriate treatment for an individual patient is becoming increasingly challenging. Natalizumab, a humanized monoclonal antibody directed against alpha4beta1 integrin, has proven short-term and long-term efficacies in terms of relapse rate reduction, prevention of disability progression, and reduction of magnetic resonance imaging-detectable activity. It is well tolerated and has further been… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 7 times. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 115 references

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

The New England journal of medicine • 2006
View 8 Excerpts
Highly Influenced

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

The New England journal of medicine • 2006
View 8 Excerpts
Highly Influenced

Can we measure long-term treatment effects in multiple sclerosis?

Nature Reviews Neurology • 2015
View 7 Excerpts
Highly Influenced

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results

Journal of neurology, neurosurgery, and psychiatry • 2014
View 5 Excerpts
Highly Influenced

CARE-MS II Investigators. CARE-MS II investigators

AJ Coles, CL Twyman, DL Arnold
2012
View 6 Excerpts
Highly Influenced